Neutral
●
PRNewsWire
●
vor 4 Monaten
BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that based on the preliminary results of its 2026 Annual Meeting of Stockholders (the "Annual Meeting") provided by its proxy solicitor, D.F.